Amarin (NASDAQ:AMRN) Announces Quarterly Earnings Results

Amarin (NASDAQ:AMRN) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.01 EPS for the quarter, beating the consensus estimate of ($1.27) by $1.28, FiscalAI reports. The company had revenue of $49.22 million for the quarter, compared to analyst estimates of $50.62 million. Amarin had a negative net margin of 38.01% and a negative return on equity of 16.31%.

Here are the key takeaways from Amarin’s conference call:

• The company struck an exclusive long-term partnership with Recordati to commercialize VAZKEPA across 59 countries, delivering a $25 million upfront payment and up to $150 million in potential milestones while shifting European promotion and commercialization to Recordati to accelerate launches and scale.
• Amarin has materially cut costs from its global restructuring—realizing about half of the estimated $70 million in annualized savings by year-end, narrowing Q4 operating losses, generating positive operating cash flow in 2025, and finishing the year with $303 million in cash and no debt.
• In the U.S., VASCEPA retains market leadership and major managed-care exclusives, but Q4 U.S. revenue fell 7% due to lower net selling price and the company expects typical Q1 volume pressure, so near-term U.S. revenue remains sensitive to pricing and exclusivity dynamics.
• Amarin emphasizes a strong clinical evidence base—supporting 45 abstracts/papers in 2025 and recent REDUCE-IT analyses showing ~25% reduction in major cardiovascular events and fewer hospitalizations—using this data to differentiate VASCEPA versus therapies like fibrates and to support global commercialization.

Amarin Trading Down 11.7%

AMRN stock traded down $1.82 during trading hours on Wednesday, hitting $13.70. 149,739 shares of the stock traded hands, compared to its average volume of 85,891. The stock has a 50-day simple moving average of $14.79 and a 200 day simple moving average of $15.78. The company has a market cap of $284.86 million, a P/E ratio of -5.52 and a beta of 0.84. Amarin has a one year low of $7.08 and a one year high of $20.90.

Hedge Funds Weigh In On Amarin

Large investors have recently made changes to their positions in the business. Banque Cantonale Vaudoise acquired a new position in shares of Amarin in the 3rd quarter worth approximately $32,000. Headlands Technologies LLC bought a new stake in Amarin during the second quarter worth approximately $44,000. Northwestern Mutual Wealth Management Co. grew its position in Amarin by 1,816.7% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 5,450 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Amarin by 56.8% in the fourth quarter. New York State Common Retirement Fund now owns 7,605 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 2,756 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in shares of Amarin by 34.8% during the 4th quarter. Wells Fargo & Company MN now owns 9,254 shares of the biopharmaceutical company’s stock valued at $129,000 after acquiring an additional 2,390 shares during the last quarter. Institutional investors own 22.25% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on AMRN shares. Wall Street Zen cut Amarin from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Amarin in a research note on Wednesday, January 21st. Finally, Zacks Research downgraded shares of Amarin from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 27th. Three research analysts have rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Strong Sell” and a consensus target price of $12.00.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.